Release Date: August 26, 2025
Expiration Date: August 26, 2026
Activity Overview
Targeted and immunological treatments are important in the standard of care for advanced and metastatic hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). In this program, expert faculty in the management of these tumors discuss the implications of recent practice-informing results from recent oncology congresses, with emphasis on the studies describing treatment options for patients with adverse risk disease features.
Target Audience
This educational activity is directed toward US-based medical oncologists, gastrointestinal oncologists, advanced practice providers, nurses, and other health care professionals who treat patients with GI cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate strategies to improve coordination and delivery of care among patients with hepatobiliary cancers.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Physician Education Resources is proud to partner with Cholangiocarcinoma Foundation (CCF).
